

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-5BCE1F15-885E-4217-9227-DCCAA0D5B8ED_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M34333_04_01
 DOI Ref: 9ju42

© 2025 USPC
 Do not distribute

Fosphenytoin Sodium Injection

DEFINITION

Fosphenytoin Sodium Injection is a sterile solution of Fosphenytoin Sodium in Water for Injection. Fosphenytoin Sodium is a prodrug. Injection containing 1 mg/mL of Fosphenytoin Sodium is equivalent to 0.667 mg/mL of Phenytoin Sodium after injection. It contains NLT 90.0% and NMT 110.0% of the labeled amount of fosphenytoin sodium ($C_{16}H_{13}N_2Na_2O_6P$).

IDENTIFICATION

Change to read:

- A. **▲SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy: 197K▲** (CN 1-MAY-2020)

Sample: Transfer a 5-mL aliquot of Injection to a 100-mL beaker. Add 30 mL of acetone to form a white precipitate, and stir for 20 min using a magnetic stirrer. Filter under vacuum, and collect the precipitate using suitable filter paper. Allow to dry under vacuum for 15 min.

Acceptance criteria: Meets the requirements

- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: 8.2 g/L of monobasic potassium phosphate in water. Adjust with 6 N potassium hydroxide solution to a pH of 6.5 ± 0.05 .

Mobile phase: Methanol, acetonitrile, and *Buffer* (25:2:73)

Standard stock solution A: 0.75 mg/mL of [USP Fosphenytoin Sodium RS](#) prepared as follows. Transfer a suitable amount of the standard in a suitable volumetric flask. Dissolve in a minimum amount of methanol. Dilute with *Buffer* to volume.

Standard stock solution B: 7.5 μ g/mL of [USP Phenytoin RS](#), 7.5 μ g/mL of [USP Phenytoin Related Compound A RS](#), and 15 μ g/mL of [USP Phenytoin Related Compound B RS](#) in methanol

Standard solution: 150 μ g/mL of [USP Fosphenytoin Sodium RS](#) from *Standard stock solution A*, 0.75 μ g/mL each of [USP Phenytoin RS](#) and [USP Phenytoin Related Compound A RS](#), and 1.5 μ g/mL of [USP Phenytoin Related Compound B RS](#) from *Standard stock solution B* in *Buffer*

Sample stock solution: Nominally 1.5 mg/mL of fosphenytoin sodium from a volume of *Injection* prepared in methanol

Sample solution: Nominally 150 μ g/mL of fosphenytoin sodium from *Sample stock solution* in *Buffer*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 214 nm

Column: 4.6-mm \times 15-cm; packing L11

Flow rate: 1.25 mL/min

Injection volume: 40 μ L

System suitability

Sample: *Standard solution*

[NOTE—See [Table 1](#) for the approximate relative retention times.]

Suitability requirements

Resolution: NLT 4.0 between phenytoin related compound B and phenytoin related compound A

Column efficiency: NLT 2250 theoretical plates for fosphenytoin

Tailing factor: NMT 1.8 for fosphenytoin

Relative standard deviation: NMT 1.0% for fosphenytoin and NMT 5.0% for phenytoin, phenytoin related compound A, and phenytoin related compound B

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of fosphenytoin sodium ($C_{16}H_{13}N_2Na_2O_6P$) in the portion of *Injection* taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of fosphenytoin sodium from the *Sample solution*

r_s = peak response of fosphenytoin sodium from the *Standard solution*

C_s = concentration of [USP Fosphenytoin Sodium RS](#) in the *Standard solution* (µg/mL) C_u = nominal concentration of fosphenytoin sodium in the *Sample solution* (µg/mL)**Acceptance criteria:** 90.0%–110.0%**IMPURITIES**• **ORGANIC IMPURITIES****Buffer, Mobile phase, Standard solution, Sample solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.**Analysis****Samples:** *Standard solution* and *Sample solution*

Calculate the percentages of phenytoin, phenytoin related compound A, and phenytoin related compound B in the portion of Injection taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

 r_u = peak response of phenytoin, phenytoin related compound A, or phenytoin related compound B from the *Sample solution* r_s = peak response of phenytoin, phenytoin related compound A, or phenytoin related compound B from the *Standard solution* C_s = concentration of the corresponding analyte in the *Standard solution* (µg/mL) C_u = nominal concentration of fosphenytoin sodium in the *Sample solution* (µg/mL)

Calculate the percentages of unspecified degradation products in the portion of Injection taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

 r_u = peak response of each unspecified degradation product from the *Sample solution* r_s = peak response of phenytoin from the *Standard solution* C_s = concentration of [USP Phenytoin RS](#) in the *Standard solution* (µg/mL) C_u = nominal concentration of fosphenytoin sodium in the *Sample solution* (µg/mL)**Acceptance criteria:** See [Table 1](#).**Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Phenytoin related compound B	0.3	1.5
Phenytoin related compound A	0.5	0.2
Fosphenytoin	1.0	—
Phenytoin	3.8	0.2
Any other individual unspecified degradation product	—	0.1
Total impurities	—	2.0

SPECIFIC TESTS

- [BACTERIAL ENDOTOXINS TEST \(85\)](#): NMT 14 USP Endotoxin Units/mL
- [pH \(791\)](#): 8.3–9.3
- **OTHER REQUIREMENTS:** It meets the requirements in [Injections and Implanted Drug Products \(1\)](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in single-dose or multiple-dose containers, preferably of Type I glass. Store between 2° and 8°. Do not store at room temperature for more than 48 h.

• **LABELING:** Both the actual content of fosphenytoin sodium and the content of phenytoin sodium, expressed in terms of phenytoin sodium equivalents, are stated on the label.

• **USP REFERENCE STANDARDS (11)**

[USP Fosphenytoin Sodium RS](#)

[USP Phenytoin RS](#)

[USP Phenytoin Related Compound A RS](#)

Diphenylglycine.

$C_{14}H_{13}NO_2$ 227.26

[USP Phenytoin Related Compound B RS](#)

Diphenylhydantoic acid.

$C_{15}H_{14}N_2O_3$ 270.29

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FOSPHENYTOIN SODIUM INJECTION	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 29(5)

Current DocID: GUID-5BCE1F15-885E-4217-9227-DCCAA0D5B8ED_4_en-US

DOI: https://doi.org/10.31003/USPNF_M34333_04_01

DOI ref: 9ju42